HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Posterior juxtascleral depot administration of anecortave acetate.

AbstractOBJECTIVE:
To develop a safe and effective transcleral delivery of anecortave acetate, a novel angiostatic cortisene, in therapeutic concentrations to the choroid and retina in the region of the macula in patients with age related macular degeneration.
METHODS:
In pre-clinical studies with rabbits and monkeys, several routes of delivery were studied including oral and other systemic routes as well as topical, subconjunctival, intravitreal injections and posterior juxtascleral administration. In addition, posterior juxtascleral depot administration using a specially designed blunt cannula was evaluated in humans.
RESULTS:
Oral and other systemic routes were not acceptable due to rapid systemic metabolism. Topical and subconjunctival administrations resulted in subtherapeutic concentrations in the macular region (<0.1 microm). Intravitreal injections resulted in adequate drug levels, but the visual axis was obscured due to the opaque nature of the drug, and this method carries risks of endophthalmitis and retinal detachment. Posterior juxtascleral depot administration in rabbits and monkeys resulted in adequate retinal and choroidal drug levels (>or=0.1 microm) up to 6 months after administration. In clinical studies, this administration technique was found to be safe.
CONCLUSIONS:
Posterior juxtascleral depot administration of anecortave acetate onto the scleral surface near the macula is a safe and effective method for delivering therapeutic concentrations of drug to the macular region of the choroid and retina for up to 6 months.
AuthorsPeter K Kaiser, Morton F Goldberg, Alberta A Davis, Anecortave Acetate Clinical Study Group
JournalSurvey of ophthalmology (Surv Ophthalmol) Vol. 52 Suppl 1 Pg. S62-9 (Jan 2007) ISSN: 0039-6257 [Print] United States
PMID17240258 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Angiogenesis Inhibitors
  • Pregnadienediols
  • anecortave acetate
Topics
  • Angiogenesis Inhibitors (administration & dosage)
  • Animals
  • Catheterization
  • Choroidal Neovascularization (drug therapy)
  • Drug Delivery Systems
  • Drug Evaluation, Preclinical
  • Humans
  • Pregnadienediols (administration & dosage)
  • Sclera

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: